Share on StockTwits
 

Ultragenyx Pharmaceutical (NASDAQ:RARE) SVP Thomas Richard Kassberg acquired 1,500 shares of the company’s stock on the open market in a transaction dated Thursday, January 30th. The shares were purchased at an average price of $21.00 per share, with a total value of $31,500.00. Following the purchase, the senior vice president now directly owns 94,350 shares in the company, valued at approximately $1,981,350. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down 7.69% on Monday, hitting $39.00. 498,216 shares of the company’s stock traded hands. Ultragenyx Pharmaceutical has a 52-week low of $38.52 and a 52-week high of $47.99. The stock’s 50-day moving average is $40.6 and its 200-day moving average is $40.6. The company’s market cap is $144.4 million.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.